17. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193–199. 18. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, et al. (2009) miR- 145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460: 705–710. 19. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, et al. (2004) MicroRNA- 143 regulates adipocyte differentiation. J Biol Chem 279: 52361–52365. 20. Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, et al. (2009) miR- 143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One 4: e7542. 21. English JM, Pearson G, Baer R, Cobb MH (1998) Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem 273: 3854–3860. 22. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, et al. (1997) BMK1/ ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 16: 7054–7066. 23. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, et al. (2010) ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med 16: 665– 670. 24. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, et al. (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 106: 3207–3212. 25. Heinlein UA (1998) Dead box for the living. J Pathol 184: 345–347. 26. Rossler OG, Hloch P, Schutz N, Weitzenegger T, Stahl H (2000) Structure and expression of the human p68 RNA helicase gene. Nucleic Acids Res 28: 932– 939. 27. Bui TV, Mendell JT (2010) Myc: Maestro of MicroRNAs. Genes Cancer 1: 568–575. Repression of Tumors in miR-143 Transgenic Mice 28. Hayashi M, Lee JD (2004) Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice. J Mol Med 82: 800–808. 29. Buzzi N, Colicheo A, Boland R, de Boland AR (2009) MAP kinases in proliferating human colon cancer Caco-2 cells. Mol Cell Biochem 328: 201–208. 30. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, et al. (2007) Myc deletion rescues Apc deficiency in the small intestine. Nature 446: 676–679. 31. Bommer GT, Fearon ER (2007) Role of c-Myc in Apc mutant intestinal phenotype: case closed or time for a new beginning? Cancer Cell 11: 391–394. 32. Hermeking H (2007) p53 enters the microRNA world. Cancer Cell 12: 414–418. 33. Bates GJ, Nicol SM, Wilson BJ, Jacobs AM, Bourdon JC, et al. (2005) The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J 24: 543–553. 34. Mishra PJ, Merlino G (2009) MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 119: 2119–2123. 35. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, et al. (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112: 4202–4212. 36. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, et al. (2010) Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 24: 2754–2759. 37. Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, et al. (2007) Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 67: 9721–9730. 38. Iwamoto T, Takahashi M, Ito M, Hamaguchi M, Isobe K, et al. (1990) Oncogenicity of the ret transforming gene in MMTV/ret transgenic mice. Oncogene 5: 535–542. 39. Tsutsui M, Hasegawa H, Adachi K, Miyata M, Huang P, et al. (2008) Establishment of cells to monitor Microprocessor through fusion genes of microRNA and GFP. Biochem Biophys Res Commun 372: 856–861. PLoS ONE | www.plosone.org 12 August 2012 | Volume 7 | Issue 8 | e42137